Powered by: Motilal Oswal
18/09/2021 2:14:12 PM | Source: ICICI Direct Ltd
Buy P&G Health Ltd For Target Rs.6,555 - ICICI Direct
News By Tags | #872 #788 #3961 #3724 #1302
Buy P&G Health Ltd For Target Rs.6,555  - ICICI Direct

Mixed quarter but decent overall yearly performance...

About the stock: Procter & Gamble Health Limited is a leading Pharma cum OTC company with key focus on Vitamins Minerals Supplement (VMS) category

* It has legacy brands in the VMS category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks)

* This company was earlier known as Merck Limited and was a part of Merck KGaA, Germany. In 2018 it (as a Consumer Health Business) was acquired by P&G.

 

Q4FY21 Results: PGHL reported mixed set of Q4FY21 results.

* Sales were up 41.9% YoY to | 285.4 crore

* EBITDA in Q4FY21 was at | 48 crore, down 8.8% YoY with margins at 17%

* Consequent PAT was at | 33.9 crore (down 30.6% YoY)

 

What should investors do? PGHL share price has grown by ~7.5x over the past five years (from ~| 728 in Aug 2016 to ~| 5530 levels in Aug 2021).

* We change our rating from HOLD to BUY rating on the stock given the good overall FY21 performance and decent growth potential for its power brands

 

Target Price and Valuation: We value PGHL at | 6555 i.e. 45x P/E on FY23E EPS

 

Key triggers for future price performance:

* P&G’s strong distribution channel and strong brand recall are likely catalysts for future growth

* MNC pharma traits like strong brand stickiness, growth, earnings visibility, consistency (despite quarterly fluctuations) in performances, strong b/s

* Key differentiator for PGHL is that its core category is VMS, which, as a therapeutic category, is likely to be rediscovered due to increased awareness post the current pandemic.

 

Alternate Stock Idea: Apart from PGHL, in our healthcare coverage we like Abbott.

* Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among others

* BUY with target price of | 20360

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer

 

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here